keyword
MENU ▼
Read by QxMD icon Read
search

fibrosis hcv

keyword
https://www.readbyqxmd.com/read/27913920/ns5a-resistance-associated-variants-undermine-the-effectiveness-of-ledipasvir-and-sofosbuvir-for-cirrhotic-patients-infected-with-hcv-genotype-1b
#1
Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi
BACKGROUND: Little real-world cohort data has been reported for Asians who have received interferon-free regimens with sofosbuvir (SOF) for chronic hepatitis C virus (HCV) infection. We evaluated the effectiveness and safety in clinical practice of ledipasvir (LDV) plus SOF for Japanese patients infected with HCV genotype 1. METHODS: This large, multicenter, real-world cohort study consisted of 772 patients treatment-naive or -experienced, with or without compensated cirrhosis, who were treated with LDV (90 mg)/SOF (400 mg) for a fixed 12-week duration...
December 2, 2016: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27910154/interferon-free-regimens-improve-portal-hypertension-and-histological-necroinflammation-in-hiv-hcv-patients-with-advanced-liver-disease
#2
P Schwabl, M Mandorfer, S Steiner, B Scheiner, D Chromy, M Herac, T Bucsics, H Hayden, K Grabmeier-Pfistershammer, A Ferlitsch, G Oberhuber, M Trauner, M Peck-Radosavljevic, T Reiberger
BACKGROUND: HIV/HCV co-infected patients show accelerated fibrosis progression and higher risk for complications of portal hypertension (PHT). AIM: To assess the effects of interferon-free therapy on portal pressure, liver histology and plasma biomarkers in HIV/HCV-coinfected patients with PHT. METHODS: Twenty-two patients with paired hepatic venous pressure gradient (HVPG) measurements prior and after successful treatment (SVR) with interferon-free regimens were included...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27898593/coinfection-with-hiv-and-hepatitis-c-virus-in-229-children-and-young-adults-living-in-europe
#3
(no author information available yet)
OBJECTIVE: To characterize children, adolescents and young adults infected with HIV/hepatitis C virus (HCV) vertically or before age of 18 years and living in Europe regarding mode of acquisition, HCV genotype, clinical status and treatment. DESIGN: Retrospective, cross-sectional study using pooled data from 11 European paediatric HIV cohorts. METHODS: Patients aged more than 18 months and less than 25 years, with HIV/HCV acquired vertically or in childhood, were included...
January 2, 2017: AIDS
https://www.readbyqxmd.com/read/27898525/characterization-of-hcv-ns3-protease-variants-in-hcv-hiv-coinfected-patients-by-ultra-deep-sequence-analysis-relationship-to-hepatic-fibrosis
#4
Enass A Abdel-Hameed, Susan D Rouster, Xiang Zhang, Jing Chen, Mario Medvedovic, Zachary D Goodman, Kenneth E Sherman
BACKGROUND: Treatment of HCV/HIV coinfection is now largely based upon utilization of direct acting agents. Pre-treatment viral resistant-associated variants (RAVs) and host liver condition may affect the sustained virological response. In this study, we explored relative prevalence of protease resistance-associated mutations, the evolution of those RAVs following 12 weeks of pegylated interferon alfa exposure, and the role hepatic fibrosis might have on RAV display. METHODS: Thirty nonresponder HCV/ HIV coinfected subjects were evaluated pre- and post- 12 weeks of pegIFN treatment...
November 25, 2016: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27882839/real-world-drug-costs-of-treating-hepatitis-c-genotypes-1-4-with-direct-acting-antivirals-initiating-treatment-at-fibrosis-0-2-and-3-4
#5
Timothy A Bach, Kathy Zaiken
BACKGROUND: Direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) have drastically improved outcomes but are also very costly. For this reason, priority for treatment is often given to patients with a higher fibrosis score at baseline by payers and providers rather than treating all eligible patients. Simulation studies have suggested that waiting to treat patients until fibrosis 3-4 may be more costly and result in worse outcomes; however, real-world implications are unknown...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27875564/donor-ifnl4-genotype-is-associated-with-early-post-transplant-fibrosis-in-recipients-with-hepatitis-c
#6
Taylor Aiken, Ari Garber, Dawn Thomas, Nicole Hamon, Rocio Lopez, Rajesh Konjeti, Arthur McCullough, Nizar Zein, John Fung, Medhat Askar, Binu V John
BACKGROUND AND AIMS: Early post-transplant hepatic fibrosis is associated with poor outcomes and may be influenced by donor/recipient genetic factors. The rs368234815 IFNL4 polymorphism is related to the previously described IL28B polymorphism, which predicts etiology-independent hepatic fibrosis. The aim of this study was to identify the impact of donor and/or recipient IFNL4 genotype on early fibrosis among patients transplanted for hepatitis C (HCV). METHODS: Clinical data were collected for 302 consecutive patients transplanted for HCV...
2016: PloS One
https://www.readbyqxmd.com/read/27875352/does-incorporating-change-in-apri-or-fib-4-indices-over-time-improve-the-accuracy-of-a-single-index-for-identifying-liver-fibrosis-in-persons-with-chronic-hepatitis-c-virus-infection
#7
Prabhu P Gounder, Celia Haering, Dana J T Bruden, Lisa Townshend-Bulson, Brenna C Simons, Philip R Spradling, Brian J McMahon
BACKGROUND: The aspartate aminotransferase-to-platelet ratio index (APRI) and a fibrosis index calculated using platelets (FIB-4) have been proposed as noninvasive markers of liver fibrosis. GOALS: To determine APRI/FIB-4 accuracy for predicting histologic liver fibrosis and evaluate whether incorporating change in index improves test accuracy in hepatitis C virus (HCV)-infected Alaska Native persons. STUDY: Using liver histology as the gold standard, we determined the test characteristics of APRI to predict Metavir ≥F2 fibrosis and FIB-4 to predict Metavir ≥F3 fibrosis...
November 21, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27862695/pan-genotypic-treatment-regimens-for-hepatitis-c-virus-advantages-and-disadvantages-in-high-and-low-income-regions
#8
REVIEW
C Hézode
During the last 5 years, the availability of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV). Compared with interferon/ribavirin-the previous standard of care-DAA combination regimens offer improved sustained virological response (SVR) rates, shorter treatment durations of 8-24 weeks, convenient once-daily single-tablet formulations and more favourable tolerability profiles. HCV treatment is complex, and the choice of therapy must consider a complex range of factors, including baseline viral load, fibrosis stage, the HCV genotype and subgenotype, and the presence of resistance-associated substitutions at baseline...
November 9, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27861593/neutrophil-and-monocyte-function-in-patients-with-chronic-hepatitis-c-undergoing-antiviral-therapy-with-regimens-containing-protease-inhibitors-with-and-without-interferon
#9
Martina Gambato, Noelia Caro-Pérez, Patricia González, Nuria Cañete, Zoe Mariño, Sabela Lens, Martín Bonacci, Concepció Bartres, José-María Sánchez-Tapias, José A Carrión, Xavier Forns, Manel Juan, Sofía Pérez-Del-Pulgar, María-Carlota Londoño
Real-life data showed an increased incidence of bacterial infections in patients with advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen against hepatitis C (HCV). However, the causes of this event are unknown. We hypothesized that PIs might impair innate immune responses through the inhibition of proteases participating in the anti-bacterial functions of neutrophils and monocytes. The aims of the study were to assess phagocytic and oxidative burst capacity in neutrophils and monocytes obtained from patients receiving a PI containing-antiviral regimen, and to determine cytokine secretion after neutrophil stimulation with flagellin...
2016: PloS One
https://www.readbyqxmd.com/read/27855947/-hepatitis-c-related-cirrhosis-current-status
#10
REVIEW
Isabel Conde, Carmen Vinaixa, Marina Berenguer
Chronic hepatitis C virus (HCV) infection affects around 150 million people. It is a leading cause of liver related morbidity and mortality through its predisposition to liver fibrosis, cirrhosis and end-stage liver complications. New treatments based on direct-acting antivirals have opened a new era in the management of HCV cirrhosis. They allow for HCV eradication without substantial side effects in almost all cirrhotic patients, reducing the risk of hepatocellular carcinoma, liver decompensation and mortality...
November 14, 2016: Medicina Clínica
https://www.readbyqxmd.com/read/27855589/twice-daily-telaprevir-for-posttransplant-genotype-1-hepatitis-c-virus-a-prospective-safety-efficacy-and-pharmacokinetics-study
#11
Raymond A Rubin, Mark W Russo, Kimberly A Brown, Robert J Fontana, Josh Levitsky, Hugo Vargas, Eric M Yoshida, Robert S Brown
OBJECTIVES: Our objective was to determine the safety, efficacy, and pharmacokinetics of telaprevir plus pegylated interferon alfa 2a and ribavirin for chronic, posttransplant genotype 1 hepatitis C virus infection. MATERIALS AND METHODS: A prospective, single-arm, multicenter, open-label, phase 2b study was conducted at 22 North American sites to assess the safety, efficacy, and pharmacokinetics of pegylated interferon alfa 2a, ribavirin, and twice daily telaprevir in liver transplant recipients with recurrent, chronic hepatitis C without cirrhosis...
November 18, 2016: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/27852847/visualizing-the-essential-role-of-complete-virion-assembly-machinery-in-efficient-hepatitis-c-virus-cell-to-cell-transmission-by-viral-infection-activated-split-intein-mediated-reporter-system-visi
#12
Fanfan Zhao, Ting Zhao, Libin Deng, Dawei Lv, Xiaolong Zhang, Xiaoyu Pan, Jun Xu, Gang Long
: Hepatitis C virus (HCV) infects 2-3% of the world population and is a leading cause of liver diseases such as fibrosis, cirrhosis and hepatocellular carcinoma. Many aspects of HCV study, ranging from molecular virology, antiviral drug development and drug resistance profiling, were supported by straightforward assays of HCV replication and infection. Among these assays, HCV-dependent fluorescence relocalization (HDFR) system allows live-cell visualization of infection without modifying viral genome, but this strategy required careful recognition of fluorescence relocalization pattern for its high fluorescence background in cytoplasm...
November 16, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27832039/a-clinician-s-guide-to-the-cost-and-health-benefits-of-hepatitis-c-cure-assessed-from-the-individual-patient-perspective
#13
Phil McEwan, Nowlan Selvapatt, Ashley Brown, Mark Thursz, Hayley Bennett, Samantha Webster, Anupama Kalsekar, Yong Yuan, Michael Brenner, Jason Gordon
BACKGROUND AND AIMS: The hepatitis C virus (HCV) remains a considerable public health challenge. Novel direct-acting antiviral (DAA) regimens offer high cure rates and the promise of reduced HCV incidence and prevalence following the up-scaling of treatment. This has focused attention towards affordability. This study aimed to estimate the economic value of cure to evaluate the treatment costs justifiable from the patient perspective. PATIENTS AND METHODS: A published, validated HCV model was utilized to contrast clinical and cost outcomes for patients aged 30-70 years, stratified by METAVIR F0-F4, for (i) no treatment and (ii) successful treatment [i...
November 9, 2016: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27831637/studies-on-the-interference-of-ganciclovir-to-hcv-liver-fibrosis
#14
J Li, C-W Pan, G-Y Zhou, L Zhuge, P-P Fang, L-X Jin, W Lin, X-Z Lin, Y Zheng
OBJECTIVE: To investigate the significance of the combined treatment with ganciclovir and interferon for patients with hepatitis C (HCV) liver fibrosis. PATIENTS AND METHODS: We retrospectively summarize 86 patients with hepatitis C treated in our hospital from October 2013 to October 2015. 49 cases, considered as control group, received combined treatment with α-interferon and ribavirin; 37 cases, considered as observation group, received combined treatment with ganciclovir and interferon...
October 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27829060/comprehensive-comparison-of-multiple-detector-computed-tomography-and-dynamic-magnetic-resonance-imaging-in-the-diagnosis-of-hepatocellular-carcinoma-with-varying-degrees-of-fibrosis
#15
Ming-Tsung Lin, Chih-Chi Wang, Yu-Fan Cheng, Hock-Liew Eng, Yi-Hao Yen, Ming-Chao Tsai, Po-Lin Tseng, Kuo-Chin Chang, Cheng-Kun Wu, Tsung-Hui Hu
BACKGROUND & AIMS: Liver computed tomography and dynamic magnetic resonance imaging play an important role in the early detection of hepatocellular carcinoma. However, the American Association for the Study of Liver Diseases (AASLD) recommend the use of applied imaging studies for HCC diagnosis only in cirrhotic patients. This study aimed to comprehensively compare liver CT and dynamic MRI for HCC diagnosis before surgical resection over years in clinical practice, and also to compare the diagnostic differences between liver CT and dynamic MRI in HCCs with varying degrees of fibrosis...
2016: PloS One
https://www.readbyqxmd.com/read/27822295/infection-with-hepatitis-viruses-fib-4-index-and-risk-of-hepatocellular-carcinoma-in-southern-italy-a-population-based-cohort-study
#16
Mario Fusco, Pierluca Piselli, Saverio Virdone, Pietro Di Cicco, Paola Scognamiglio, Paolo De Paoli, Valerio Ciullo, Diana Verdirosi, Michele D'Orazio, Luigino Dal Maso, Enrico Girardi, Silvia Franceschi, Diego Serraino
BACKGROUND: The incidence of hepatocellular carcinoma (HCC) and its association with hepatitis C (HCV) and hepatitis B virus (HBV) infections, FIB-4 index and liver enzymes was assessed in an area of the province of Naples covered by a population-based cancer registry. METHODS: We conducted a cohort investigation on 4492 individuals previously enrolled in a population-based seroprevalent survey on HCV and HBV infections. The diagnosis of HCC was assessed through a record linkage with the cancer registry...
2016: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/27818234/long-term-effect-of-sustained-virological-response-on-hepatocellular-carcinoma-in-patients-with-hepatitis-c-in-canada
#17
Naveed Z Janjua, Mei Chong, Margot Kuo, Ryan Woods, Jason Wong, Eric M Yoshida, Morris Sherman, Zahid A Butt, Hasina Samji, Darrel Cook, Amanda Yu, Maria Alvarez, Mark Tyndall, Mel Krajden
BACKGROUND: We evaluated the effect of sustained virological response(SVR) on the HCC risk and estimated HCC incidence post SVR in a large population-based cohort in Canada. METHODS: The BC Hepatitis Testers Cohort(BC-HTC) includes individuals tested for HCV between 1990-2013 linked with data on their medical visits, hospitalizations, cancers, prescription drugs and mortality. Patients receiving interferon-based HCV treatments were followed from the end of treatment to HCC diagnosis, death or December 31, 2012...
November 3, 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27813284/functional-connectivity-alterations-in-patients-with-chronic-hepatitis-c-virus-infection-a-multimodal-mri-study
#18
S Kharabian Masouleh, S Herzig, L Klose, E Roggenhofer, H Tenckhoff, T Kaiser, A Thöne-Otto, M Wiese, T Berg, M L Schroeter, D S Margulies, A Villringer
Chronic hepatitis C virus (HCV) infection is associated with fatigue and depression. Cognitive impairments are also reported in a smaller number of HCV-positive patients. Recent studies linked HCV to low-grade inflammation in brain. Here, we test the hypothesis that chronic HCV is associated with 3T-neuroimaging-derived grey matter volume (GMV) and functional connectivity alterations in a sample of chronic HCV (1b), without severe liver disease. Regional GMV and resting-state fMRI-derived eigenvector centrality (EC) were compared between 19 HCV-positive patients and 23 healthy controls (all females, 50-69 and 52-64 years, respectively), controlling for white matter hyperintensities and age...
November 4, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27813162/do-directly-acting-antiviral-agents-for-hcv-increase-the-risk-of-hepatic-decompensation-and-decline-in-renal-function-results-from-erchives
#19
A A Butt, Y Ren, K Marks, O S Shaikh, K E Sherman
BACKGROUND: Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre-treatment cirrhosis, but this risk is not well defined. AIM: To determine the incidence of hepatic decompensation, liver transplantation, death and worsening renal function in patients treated with a Paritaprevir/ritonavir, Ombitasvir, Dasabuvir (PrOD), sofosbuvir/simeprevir or sofosbuvir/ledipasvir regimen. METHODS: We followed ERCHIVES participants treated with the above regimens for up to 12 weeks post-treatment...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27813124/noninvasive-markers-for-staging-fibrosis-in-chronic-delta-hepatitis
#20
V Takyar, P Surana, D E Kleiner, K Wilkins, J H Hoofnagle, T J Liang, T Heller, C Koh
BACKGROUND: Serum fibrosis markers are useful in staging chronic hepatitis B (HBV) and C (HCV) virus but have not been evaluated in chronic hepatitis D virus (HDV). AIM: To evaluate the utility of serum fibrosis markers [fibrosis-4 score (FIB-4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio, aspartate aminotransferase ratio (AAR), age-platelet index (API), AST-to-platelet-ratio-index (APRI) and Hui score] in HDV infection. METHODS: Clinical and histologic laboratory data from HBV, HCV and HDV patients were evaluated and serum fibrosis markers were calculated...
January 2017: Alimentary Pharmacology & Therapeutics
keyword
keyword
94653
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"